Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)
Launched by MERCK SHARP & DOHME LLC · Nov 29, 2023
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment called MK-6194 for adults with Systemic Lupus Erythematosus (SLE), a condition where the immune system mistakenly attacks healthy tissues. The main goal is to see if MK-6194 works better than a placebo (a fake treatment) in helping people with SLE feel better by the end of 28 weeks. To be eligible for the trial, participants must have been diagnosed with SLE for at least six months, be currently taking certain medications for their condition, and have specific symptoms related to SLE, such as a rash or swollen joints.
Participants in the trial will receive either MK-6194 or a placebo and will be monitored closely by healthcare professionals. It's important to note that some individuals may not qualify, especially those with serious heart or lung conditions, certain infections, or who are taking multiple immune-suppressing medications. This trial is currently recruiting participants, and those who are eligible can expect regular check-ins and assessments to track their progress and any side effects from the treatment.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Has a diagnosis of systemic lupus erythematosus (SLE) ≥6 months prior to Screening.
- • Is taking at least 1 background therapy (1 immunosuppressant or dapsone and/or 1 antimalarial and/or oral corticosteroids) for SLE.
- • Has + antinuclear antibody (+ANA) (titer ≥1:80) or positive anti-double-strand deoxyribonucleic acid (dsDNA) antibody or positive anti-Sm antibody, or positive anti-SSA/Ro antibody.
- • Has the presence of at least one of the following manifestations of SLE: Active lupus rash with CLASI-A erythema and scale/hypertrophy combined score \>2, or \>2 tender and swollen joints in wrists, metacarpophalangeals (MCPs), or proximal interphalangeals (PIPs).
- • Has a hybrid Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) total score of ≥6 and clinical hybrid SLEDAI score of ≥4.
- Exclusion Criteria:
- • Has a concurrent clinically significant disease or clinically relevant laboratory abnormalities, or a history of any illness or medical condition that, in the opinion of the investigator, might confound the results of the study or poses an additional risk to the participant by their participation in the study.
- • Has symptomatic heart failure (New York Heart Association class III or IV) or myocardial infarction or unstable angina pectoris within 6 months prior to Screening.
- • Has a severe chronic pulmonary disease requiring oxygen therapy.
- • Has a transplanted organ which requires continued immunosuppression.
- • Has a known systemic hypersensitivity to IL-2, or modified IL-2 including MK-6194, or its inactive ingredients.
- • Has a known history of lymphoproliferative disease, including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy and/or splenomegaly.
- • Has drug-induced cutaneous lupus erythematosus (CLE) and/or drug-induced SLE in the setting of continued treatment with a causative agent.
- • Has active or unstable neuropsychiatric lupus including but not limited to the following: seizure, new or worsening impaired level of consciousness, psychosis, delirium or confused state, aseptic meningitis, cranial neuropathy, cerebrovascular accident, ascending or transverse myelitis, chorea, cerebellar ataxia, mononeuritis multiplex, or demyelinating syndromes.
- • Has a diagnosis of Antiphospholipid Syndrome with history of vascular thrombosis, catastrophic APS, or pregnancy morbidity within 6 months prior to Screening.
- • Has a history of any malignancy, except for successfully treated non-melanoma skin cancer or localized carcinoma in situ of the cervix.
- • Has an active or clinically significant infection requiring hospitalization or treatment with anti-infectives.
- • Has evidence of active tuberculosis (TB), latent TB, or inadequately treated TB.
- • Has confirmed or suspected COVID-19 infection.
- • Has had major surgery within 3 months prior to Screening or has a major surgery planned during the study.
- • Is taking more than 1 immunosuppressant.
- • Is taking more than 1 oral NSAID (excluding low-dose aspirin \[\<350 mg/day\]) or is taking daily oral nonsteroidal anti-inflammatory drug (NSAID) at greater than the maximum recommended dosage.
- • Is currently on any chronic systemic (oral or IV) anti-infective therapy for chronic active infection (such as pneumocystis, cytomegalovirus, herpes zoster, or atypical mycobacteria).
About Merck Sharp & Dohme Llc
Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., is a leading global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines and vaccines that address unmet medical needs. With a strong focus on research and development, Merck Sharp & Dohme leverages advanced science and technology to enhance patient outcomes across various therapeutic areas, including oncology, infectious diseases, and cardiovascular health. Committed to ethical practices and regulatory compliance, the company actively engages in clinical trials to advance medical knowledge and improve health care for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Merida, Yucatan, Mexico
Barranquilla, Atlantico, Colombia
La Palma, California, United States
Clearwater, Florida, United States
Charlotte, North Carolina, United States
Charlotte, North Carolina, United States
Sherbrooke, Quebec, Canada
Chiba, , Japan
Desoto, Texas, United States
La Serena, Coquimbo, Chile
Santiago, Region M. De Santiago, Chile
La Serena, Coquimbo, Chile
Izumo, Shimane, Japan
Okayama, , Japan
Santiago, Region M. De Santiago, Chile
Saint Priest En Jarez, Loire, France
Bydgoszcz, Kujawsko Pomorskie, Poland
Lublin, Lubelskie, Poland
A Coruña, La Coruna, Spain
Valencia, Valenciana, Comunitat, Spain
Denver, Colorado, United States
Plantation, Florida, United States
Temuco, Araucania, Chile
Nagoya, Aichi, Japan
Shimotsuga, Tochigi, Japan
Krakow, Malopolskie, Poland
Bialystok, Podlaskie, Poland
Barcelona, , Spain
Sevilla, , Spain
Sendai Shi, Miyagi, Japan
Chiba, , Japan
Lyon, Rhone Alpes, France
Guatemala, , Guatemala
Guatemala, , Guatemala
Rome, Roma, Italy
Osaka, , Japan
Valladolid, , Spain
Ciudad De Guatemala, , Guatemala
Lille, Nord, France
Santiago, Region M. De Santiago, Chile
Taiping, Perak, Malaysia
Poznan, Wielkopolskie, Poland
Pessac, Aquitaine, France
Montpellier, Herault, France
Siena, Toscana, Italy
Kuantan, Pahang, Malaysia
Bytom, Slaskie, Poland
Poznan, Wielkopolskie, Poland
Guiyang, Guizhou, China
Barranquilla, Atlantico, Colombia
Chía, Cundinamarca, Colombia
Toulouse, Haute Garonne, France
Kawasaki, Kanagawa, Japan
Zipaquira, Cundinamarca, Colombia
Cali, Valle Del Cauca, Colombia
Itabashiku, Tokyo, Japan
Osaka, , Japan
San M. De Tucuman, Tucuman, Argentina
Porto Alegre, Rio Grande Do Sul, Brazil
Temuco, Araucania, Chile
Beijing, Beijing, China
Guangzhou, Guangdong, China
Nantong, Jiangsu, China
Shanghai, Shanghai, China
Medellín, Antioquia, Colombia
Cali, Valle Del Cauca, Colombia
Tomigusuku, Okinawa, Japan
Shinagawa, Tokyo, Japan
Lembah Pantai, Kuala Lumpur, Malaysia
San Luis Potosí, San Luis Potosi, Mexico
Distrito Federal, , Mexico
Rosario, Santa Fe, Argentina
Mendoza, , Argentina
São José Do Rio Preto, Sao Paulo, Brazil
Recoleta, Region M. De Santiago, Chile
Hengyang, Hunan, China
Baotou, Inner Mongolia, China
Pingxiang, Jiangxi, China
Roma, Lazio, Italy
Mar Del Plata, Buenos Aires, Argentina
Tampa, Florida, United States
Porto Alegre, Rio Grande Do Sul, Brazil
Sao Bernardo Do Campo, Sao Paulo, Brazil
Lanzhou, Gansu, China
Shijiazhuang, Hebei, China
Wuhan, Hubei, China
Chengdu, Sichuan, China
Tianjin, Tianjin, China
Memphis, Tennessee, United States
Guangzhou, Guangdong, China
Xi'an, Shaanxi, China
Guadalajara, Jalisco, Mexico
Guadalajara, Jalisco, Mexico
Wuhan, Hubei, China
Napoli, , Italy
Santa Fe, , Argentina
Bengbu, Anhui, China
Chang Chun, Jilin, China
Taiyuan, Shanxi, China
Tujunga, California, United States
La Serena., Coquimbo, Chile
Houston, Texas, United States
Bengbu, Anhui, China
Luoyang, Henan, China
Lake Charles, Louisiana, United States
Grand Blanc, Michigan, United States
Mesquite, Texas, United States
Guadalajara, Jalisco, Mexico
Chihuahua, , Mexico
Baytown, Texas, United States
Rozzano, Milano, Italy
León, Guanajuato, Mexico
Iloilo, , Philippines
Covina, California, United States
Mexico City, Distrito Federal, Mexico
Lipa, Batangas, Philippines
Quezon City, National Capital Region, Philippines
Lipa City, Batangas, Philippines
Hefei, Anhui, China
Roma, , Italy
Oklahoma City, Oklahoma, United States
Osaka, , Japan
Kadikoy, Istanbul, Turkey
Ankara, , Turkey
Sakarya, , Turkey
Santa Fe., Santa Fe, Argentina
Sherbrooke, Quebec, Canada
Santiago., Region M. De Santiago, Chile
Rosario, Santa Fe, Argentina
Guadalajara, Jalisco, Mexico
Warszawa, Mazowieckie, Poland
Ankara, , Turkey
Shinagawa, Tokyo, Japan
Chiba, , Japan
Monterrey, Nuevo Leon, Mexico
Atlanta, Georgia, United States
La Jolla, California, United States
La Serena., Coquimbo, Chile
Firenze, , Italy
Mexico City, Distrito Federal, Mexico
La Jolla, California, United States
Santiago., Region M. De Santiago, Chile
Guangzhou, Guangdong, China
Baotou, Inner Mongolia, China
Napoli, , Italy
Merida, Yucatan, Mexico
Cheras, Kuala Lumpur, Malaysia
Padova, Veneto, Italy
Cuiaba, Mato Grosso, Brazil
Valencia, , Spain
Patients applied
Trial Officials
Medical Director
Study Director
Merck Sharp & Dohme LLC
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported